# Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

> **NCT07139509** · PHASE1 · RECRUITING · sponsor: **Xi'an No.3 Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma(MM)

## Interventions

- **DRUG:** allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells

## Key facts

- **NCT ID:** NCT07139509
- **Lead sponsor:** Xi'an No.3 Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-03
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07139509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07139509, "Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07139509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*